This study identifies mTOR signaling as a therapeutic target in AXL-deficient advanced prostate cancer through kinase inhibitor screening and functional analysis.

bioRxiv · Oct 14, 2026 · PreprintCancer Biology

Beyond Dmax and DC50: A simple tool to evaluate the complex PROTAC-mediated kinetic degradation dynamics

Smitha Kizhake, Amarnath Natararajan

The paper introduces a simple live-cell imaging assay to rapidly measure multiple PROTAC degradation metrics for comparing and ranking PROTACs.

bioRxiv · Sep 22, 2026 · PreprintMolecular Biology

Fluorescence based live cell imaging identifies exon 14 skipped hepatocyte growth factor receptor (MET) degraders

Jayapal Reddy Mallareddy, Lin Yang, Wan‐Hsin Lin, Ryan W. Feathers, Jennifer R. Ayers-Ringler, Ezequiel J. Tolosa, Amritha G. Kizhake, Smitha Kizhake, Sydney P. Kubica, Lidia Boghean, Sophie Alvarez, Michael J. Naldrett, Sarbjit Singh, Sandeep Rana, Muhammad Zahid, , Aaron Scott Mansfield

The paper identifies a potent MET degrader using live cell imaging, showing it is more effective than existing PROTACs.

RSC Advances · Jan 1, 2025Peer-reviewedCancer Biology